BioPharmSignal logoBioPharmSignal

Biotech News

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Protara Therapeutics (TARA)Protara TherapeuticsConference / presentation

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C.

Related news

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

KRYSKrystal Biotech2026-09-03 12:00 EST

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

View all latest news

Protara Therapeutics

Cancer and Rare-Disease Company Protara Therapeutics develops therapies for cancer and rare diseases, with programs spanning cell-based immunopotentiation and phospholipid substrate replacement. Bladder Cancer The ADVANCED program evaluates intravesical TARA-002 in high-grade non-muscle-invasive bladder cancer across BCG-unresponsive,...

Recent company news

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

TARAProtara Therapeutics2026-05-20 12:00 EST

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

Stock data

Close
2.56 USD
Market cap
243.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States